I'm LongbridgeAI, I can summarize articles.Acrux Limited has sold its US rights for Prilocaine 2.5% and Lidocaine 2.5% Cream for $550,000. The proceeds will support the development of Hormone Replacement Therapy products. This move aligns with Acrux's strategy to focus on more promising revenue-generating products. The latest analyst rating for Acrux stock is a Hold with a A$0.01 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Acrux ( (AU:ACR) ) is now available.
Acrux Limited has divested its Prilocaine 2.5% and Lidocaine 2.5% Cream registration and distribution rights in the US for $550,000, as the product no longer contributes significantly to its portfolio. The proceeds from this divestment will be used to support the development of Hormone Replacement Therapy products, aligning with Acrux’s strategy to optimize its portfolio and focus on more promising revenue-generating products.
The most recent analyst rating on (AU:ACR) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Acrux stock, see the AU:ACR Stock Forecast page.
More about Acrux
Acrux is a dynamic Australian drug delivery company focused on developing and commercializing patient-preferred healthcare products for global markets. The company creates economic value by leveraging talented individuals to develop and commercialize healthcare products using proprietary or acquired technologies, with a focus on innovative drug delivery.
Average Trading Volume: 275,638
Technical Sentiment Signal: Sell
Current Market Cap: A$6.57M
For an in-depth examination of ACR stock, go to TipRanks’ Overview page.